Answers are grounded in this paper and cite their sources.
Background Hepatitis B virus (HBV) is the pathogen that causes viral hepatitis type B and is highly contagious. In severe cases, it can lead to hepatocellular carcinoma (HCC). Although oleanolic acid (OA) can be used for the treatment of viral hepatitis type B, its mechanism in HBV-related hepatocellular carcinoma (HBV-HCC) remains unclear.This study aims to reveal the anti-cancer effect of OA and the key regulatory role of its non-coding RNA in the occurrence and progression of HBV-HCC. Methods This study utilized cell proliferation and migration assays, along with RNA sequencing technology, to systematically examine how OA affects the biological characteristics of HBV-HCC cells. Furthermore, combining these findings with functional studies and subcutaneous tumor formation experiments in nude mice, we delve into the mechanisms by which OA impacts HBV-HCC under varying levels of SNHG18 expression. RT-qPCR was performed to evaluate expression levels of lncRNA SNHG18 and HBx on tumor tissues and peri-tumoral tissues of 111 HBV-HCC patients. Potential targets of miRNA related to SNHG18 predicted using LncBase database were investigated for further validation in human cell lines (HepG2 and HepG2/2.2.15 cells) with transfection with relevant plasmids in different experimental groups. Expression level of HBx in the cell lines obtained as per standard methods was altered by transfection with plasmids or siRNA respectively. The SNHG18 and miR-300 expression of these cell lines in all groups were evaluated by RT-qPCR. Expression of HBx after OA treatment was evaluated using ELISA, western blot and RT-qPCR. Luciferase reporter assays used to determine effects of HBx on promoter activity for SNHG18. Mutation of binding sites of miR-300 with SNHG18 and evaluation on luciferase was carried out further. Results OA proves highly effective in curbing the proliferation, migration capabilities, and epithelial-mesenchymal transition (EMT) process in HBV-HCC, with transcriptome sequencing data revealing a downward trend in the expression levels of numerous signaling pathways that fuel tumor development. Further investigation demonstrates that OA accomplishes this by activating SNHG18 gene expression, which in turn suppresses the proliferative capacity of HBV-HCC cells and effectively halts the progression of EMT. HBV-associated HCC tissues had decreased expression of SNHG18 relative to peri-tumoral tissues. However, downregulated expression of SNHG18 via miR-300 wasn't due to suppression of promoter transcription. OA inhibited HBx-induced increase of miR-300 expression, which restored SNHG18 expression as evidenced by quantitative data. The precise transcription factor (s) or cofactor (s) linking HBx to miR-300 transcription remain undefined and require further investigation. Conclusions This study demonstrates that OA can effectively hinder the progression of HBV-HCC through the molecular pathway mediated by SNHG18. Specifically, the overexpression of HBx protein within HBV-HCC cells results in an increase in miR-300 expression, which in turn suppresses SNHG18 expression. OA, however, counters the HBx-induced activation of miR-300, reversing the suppressive effect and restoring SNHG18 expression levels. OA has potential in reducing HBV-associated hepatocellular carcinoma growth, suggesting this drug has significant role in management HBV and thus could be considered as antitumor agent to treat HBV-associated hepatocellular carcinoma.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: